Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 66.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 33.3%High 0 · 0%

Summary of findings: bevacizumab vs ranibizumab

Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration

Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 1.15 [0.99, 1.34]
6 studies · 3365 participants
Moderate

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

Systemic adverse events at · adults with centre‐involving diabetic macular oedema

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

Systemic adverse events at · adults with centre‐involving diabetic macular oedema

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found